MEDI-545
Phase 2Small molecule
AstraZenecaMEDI-545 is one of 79 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.
2
Indications
6
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Stelara
Johnson & JohnsonPhase 3
Rinvoq
AbbViePhase 3
Ocrevus
RochePhase 3
Gazyva
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Intrarosa
Alnylam PharmaceuticalsPhase 3
Rayos
RRoxane Laboratories
Phase 3
Benadryl
PParkedale
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Systemic Lupus Erythematosus3 trials
Lupus1 trial
Dermatomyositis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MEDI-545. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company